We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Immunocore Holdings PLC Sponsored ADR is one of 1184 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Immunocore Holdings PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for IMCR's full-year earnings has moved 44.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, IMCR has gained about 27.6% so far this year. Meanwhile, the Medical sector has returned an average of -22.3% on a year-to-date basis. This means that Immunocore Holdings PLC Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, vTv Therapeutics (VTVT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 2.5%.
In vTv Therapeutics' case, the consensus EPS estimate for the current year increased 22.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Immunocore Holdings PLC Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 557 individual companies and currently sits at #74 in the Zacks Industry Rank. Stocks in this group have lost about 25.9% so far this year, so IMCR is performing better this group in terms of year-to-date returns. vTv Therapeutics is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Immunocore Holdings PLC Sponsored ADR and vTv Therapeutics as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Immunocore Holdings PLC Sponsored ADR is one of 1184 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Immunocore Holdings PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for IMCR's full-year earnings has moved 44.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, IMCR has gained about 27.6% so far this year. Meanwhile, the Medical sector has returned an average of -22.3% on a year-to-date basis. This means that Immunocore Holdings PLC Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, vTv Therapeutics (VTVT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 2.5%.
In vTv Therapeutics' case, the consensus EPS estimate for the current year increased 22.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Immunocore Holdings PLC Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 557 individual companies and currently sits at #74 in the Zacks Industry Rank. Stocks in this group have lost about 25.9% so far this year, so IMCR is performing better this group in terms of year-to-date returns. vTv Therapeutics is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Immunocore Holdings PLC Sponsored ADR and vTv Therapeutics as they attempt to continue their solid performance.